Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
N/A
N/A
80 Years
N/A
80 Years
Open (Enrolling)
Female
Polymorphism, CYP19, Aromatase Inhibitor
Female
Polymorphism, CYP19, Aromatase Inhibitor
Trial Information
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Inclusion Criteria:
- hormone receptor positiveBreast cancer patient
- postmenopausal women
- first user of aromatase inhibitor
Exclusion Criteria:
- premenopausal
- The patient who take the other antihormonal therapy
- osteoporosis patients
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
The prevalence of CYP19 polymorphism
Outcome Time Frame:
12. 31. 2011
Safety Issue:
No
Principal Investigator
Seok Jin Nam, M.D., Ph.D.
Investigator Role:
Study Director
Investigator Affiliation:
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery
Authority:
South Korea: Institutiona Review Board
Study ID:
2009-11-035
NCT ID:
NCT01137136
Start Date:
June 2010
Completion Date:
December 2015
Related Keywords:
- Polymorphism
- CYP19
- Aromatase Inhibitor
- Breast Neoplasms
Name | Location |
|---|
